참고문헌
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, Team WLC. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671. https://doi.org/10.1371/journal.pone.0035671
- Papadopoulou B, Huang XF, Boucher N, McNicoll F. Stage-specific regulation of gene expression in Leishmania. ASM News, American Society for Microbiology 2003; 69: 282-288.
- Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE,Wilson ME. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 2001; 167: 893-901. https://doi.org/10.4049/jimmunol.167.2.893
- Garg R, Gupta S, Tripathi P, Naik S, Sundar S, Dube A. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol 2005; 140: 149-156. https://doi.org/10.1111/j.1365-2249.2005.02745.x
- Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincendeau P, Lemesre JL. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect Immun 2002; 70: 3727-3735. https://doi.org/10.1128/IAI.70.7.3727-3735.2002
- Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol 2009; 47: 412.
- Kram D, Thale C, Kolodziej H, Kiderlen AF. Intracellular parasite kill: flow cytometry and NO detection for rapid discrimination between anti-leishmanial activity and macrophage activation. J Immunol Methods 2008; 333: 79-88. https://doi.org/10.1016/j.jim.2008.01.004
- Gupta S, Sundar S, Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother 2005; 49: 3776-3783. https://doi.org/10.1128/AAC.49.9.3776-3783.2005
- Rocha MN, Correa CM, Melo MN, Beverley SM, Martins-Filho OA, Madureira AP, Soares RP. An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein. Diagn Microbiol Infect Dis 2013; 75: 282-291. https://doi.org/10.1016/j.diagmicrobio.2012.11.018
- Avlonitis N, Lekka E, Detsi A, Koufaki M, Calogeropoulou T, Scoulica E, Siapi E, Kyrikou I, Mavromoustakos T, Tsotinis A. Antileishmanial ring-substituted ether phospholipids. J Med Chem 2003; 46: 755-767. https://doi.org/10.1021/jm020972c
- Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue(R). Parasitol Int 2000; 48: 265-269. https://doi.org/10.1016/S1383-5769(99)00020-3
- Bodley AL, McGarry MW, Shapiro TA. Drug cytotoxicity assay for African trypanosomes and Leishmania species. J Infect Dis 1995; 172: 1157-1159. https://doi.org/10.1093/infdis/172.4.1157
- Croft S. In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis. Parasitol Today 1986; 2: 64-69. https://doi.org/10.1016/0169-4758(86)90157-2
- Gupta S. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res 2011; 133: 27.
- Lang T, Goyard S, Lebastard M, Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 2005; 7: 383-392. https://doi.org/10.1111/j.1462-5822.2004.00468.x
- Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 2009; 25: 432-439. https://doi.org/10.1016/j.pt.2009.06.006
- Naylor LH. Reporter gene technology: the future looks bright. Biochem Pharmacol 1999; 58: 749-757. https://doi.org/10.1016/S0006-2952(99)00096-9
- Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob Agnts J 2009; 1: 9-19.
- Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, Seyed N, Torkashvand F, Vaziri B, Rafati S. Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 2011; 127: 637-645. https://doi.org/10.1016/j.exppara.2010.12.006
- Gangwar S, Goyal N. Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds. Curr Microbiol 2012; 65: 696-700. https://doi.org/10.1007/s00284-012-0209-1
- Wu Y, Liao Q, Yang R, Chen X, Chen X. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Res 2011; 155: 406-414. https://doi.org/10.1016/j.virusres.2010.11.009
- Vaughan AM, Mikolajczak SA, Camargo N, Lakshmanan V, Kennedy M, Lindner SE, Miller JL, Hume JC, Kappe SH. A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol Biochem Parasitol 2012; 186: 143-147. https://doi.org/10.1016/j.molbiopara.2012.10.004
-
Taheri T, Saberi Nik H, Seyed N, Doustdari F, Etemadzadeh MH, Torkashvand F, Rafati S. Generation of stable L.
$major^{+EGFP-LUC }$ and simultaneous comparison between EGFP and luciferase sensitivity. Exp Parasitol 2015; 150: 44-55. https://doi.org/10.1016/j.exppara.2015.01.008 - Jain SK, Sahu R, Walker LA, Tekwani BL. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp 2012; (70): e4054.
- Michel G, Ferrua B, Lang T, Maddugoda MP, Munro P, Pomares C, Lemichez E, Marty P. Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro. PLoS Negl Trop Dis 2011; 5: e1323. https://doi.org/10.1371/journal.pntd.0001323
- Mehta SR, Zhang X-Q, Badaro R, Spina C, Day J, Chang KP, Schooley RT. Flow cytometric screening for anti-leishmanials in a human macrophage cell line. Exp Parasitol 2010; 126: 617-620. https://doi.org/10.1016/j.exppara.2010.06.007
- Ploemen IH, Prudencio M, Douradinha BG, Ramesar J, Fonager J, van Gemert G-J, Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One 2009; 4: e7881. https://doi.org/10.1371/journal.pone.0007881
- Shio MT, Olivier M. Editorial: Leishmania survival mechanisms: the role of host phosphatases. J Leukoc Biol 2010; 88: 1-3. https://doi.org/10.1189/jlb.0210088
- Balestieri F, Queiroz A, Scavone C, Costa V, Barral-Netto M, Abrahamsohn IA. Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microb Infect 2002; 4: 23-29. https://doi.org/10.1016/S1286-4579(01)01505-2
- Pearson R, Harcus J, Symes P, Romito R, Donowitz G. Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol 1982; 129: 1282-86.
- Paloque L, Vidal N, Casanova M, Dumètre A, Verhaeghe P, Parzy D, Azas N. A new, rapid and sensitive bioluminescence assay for drug screening on Leishmania. J Microbiol Methods 2013; 95: 320-323. https://doi.org/10.1016/j.mimet.2013.09.006
- Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001; 45: 1168-1173. https://doi.org/10.1128/AAC.45.4.1168-1173.2001
- Reimao JQ, Trinconi CT, Yokoyama-Yasunaka JK, Miguel DC, Kalil SP, Uliana SR. Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool. J Microbiol Methods 2013; 93: 95-101. https://doi.org/10.1016/j.mimet.2013.02.007
피인용 문헌
- EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice vol.100, pp.9, 2016, https://doi.org/10.1007/s00253-015-7201-1
- Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites vol.11, pp.7, 2017, https://doi.org/10.1371/journal.pntd.0005774
- Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice vol.11, pp.12, 2017, https://doi.org/10.1371/journal.pntd.0006123
- Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays vol.12, pp.7, 2015, https://doi.org/10.1371/journal.pntd.0006639
- In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates vol.13, pp.12, 2015, https://doi.org/10.1371/journal.pntd.0007885
- Potential of the natural products against leishmaniasis in Old World - a review of in-vitro studies vol.114, pp.4, 2015, https://doi.org/10.1080/20477724.2020.1754655
- Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review vol.10, pp.12, 2015, https://doi.org/10.3390/pathogens10121608